Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial

Autor: Perez-Valero, I, Pasquau, J, Rubio, R, Rivero, A, Santos, J, Sanz, J, Marino, A, Crespo, M, Hernandez-Quero, J, Antonio Iribarren, J, Gutierrez, F, Terron, A, Esteban, H, Antonio Perez-Molina, J, GESIDA 7011 Study Grp

Publikováno v: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

Background: Concerns have been voiced over the capacity of deintensification strategies to preserve neurocognitive function and prevent neurocognitive impairment. Methods: We present the 96 week results of a neurocognitive substudy nested within the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae3a79bfe753cfbeda484330a40eddd0
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=3829

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.